Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Encenicline extension study in Alzheimer's disease
NCT02004392Phase 3Terminated
- Sponsor
- FORUM Pharmaceuticals
- Start
- Jun 2014
- Primary completion
- Aug 2017
- Modality
- Small Molecules
- Countries
- 12
01
Overview
A Phase 3 trial of encenicline in Alzheimer's disease (AD), sponsored by FORUM Pharmaceuticals. Started Jun 2014; status: terminated.
02
Drugs
encenicline
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT02004392.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02004392.